Health Care

Mylan Executives Unlikely to Lose Pay Over EpiPen Issue

Executives of EpiPen maker Mylan NV are unlikely to suffer a reduction in their pay from the company's recent $465 million settlement of allegations that it improperly overcharged Medicaid for the lifesaving drug.

Aetna's 3Q Earnings Rise 8%

Aetna, No. 3 U.S. health insurer, reported an 8 percent rise in quarterly profit as memberships grew in its government business, which sells Medicaid and Medicare plans.